Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Melanoma-associated retinopathy (MAR) is a rare autoimmune condition that occurs in some people with melanoma (a type of skin cancer) and can affect the vision.
Biomarker and diagnostic research for melanoma associated retinopathy has been reported in the published literature.
No clinical trials have been registered for melanoma associated retinopathy.
18 publications have been identified in PubMed for melanoma associated retinopathy. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (44%), and Diagnostic / Biomarker (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 | 50% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 5:33 AM UTC
Genetic and Rare Diseases Info Center
8 |
44% |
Testing and diagnosis research | 1 | 6% |
Sant Albors M (2026). [PMID: 41413897](https://pubmed.ncbi.nlm.nih.gov/41413897/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
Mukundan A (2026). [PMID: 41316839](https://pubmed.ncbi.nlm.nih.gov/41316839/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Singh D (2026). [PMID: 35201711](https://pubmed.ncbi.nlm.nih.gov/35201711/). *Unknown Journal*. [Review / Meta-Analysis]
Zhao CS (2026). [PMID: 41608829](https://pubmed.ncbi.nlm.nih.gov/41608829/). *Curr Opin Ophthalmol*. [Review / Meta-Analysis]
Natividade MS (2026). [PMID: 41852360](https://pubmed.ncbi.nlm.nih.gov/41852360/). *Am J Ophthalmol Case Rep*. [Case Report / Case Series]
Sarıgül Sezenöz A (2026). [PMID: 41835104](https://pubmed.ncbi.nlm.nih.gov/41835104/). *Ocul Oncol Pathol*. [Diagnostic / Biomarker]
Elbasiony E (2025). [PMID: 40862484](https://pubmed.ncbi.nlm.nih.gov/40862484/). *Curr Opin Ophthalmol*. [Review / Meta-Analysis]
Barsi H (2025). [PMID: 41319252](https://pubmed.ncbi.nlm.nih.gov/41319252/). *Orv Hetil*. [Review / Meta-Analysis]
Kalogeropoulos D (2025). [PMID: 40824502](https://pubmed.ncbi.nlm.nih.gov/40824502/). *Int Ophthalmol*. [Review / Meta-Analysis]
Seidler KM (2025). [PMID: 39387565](https://pubmed.ncbi.nlm.nih.gov/39387565/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
AI-curated news mentioning melanoma associated retinopathy
Updated Aug 19, 2026
Moderna's stock surged nearly 100% as their mRNA cancer vaccine, developed in partnership with Merck, demonstrated a significant delay in melanoma recurrence in a Phase 3 trial. The companies plan to submit the data to the FDA for potential approval.